Biotech Values

[DewDiligence]

Bavarian Nordic Starts Phase-1/2 Trial of Prostate-Cancer Vaccine

http://biz.yahoo.com/prnews/080603/3672716en_public.html

>>
Tuesday June 3, 3:36 am ET

KVISTGÅRD, Denmark, June 3 /PRNewswire/ -- Bavarian Nordic's subsidiary, BN ImmunoTherapeutics has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.

A Phase I/II safety and tolerability study in 18 male patients with non-metastatic as well as hormone-insensitive prostate cancer has begun enrolment in the US. Secondary objectives of the trial include examining the ability of the vaccine to induce prostate antigen-specific immune responses, as well as clinical anti-tumour activity. Preliminary data is expected during second half year 2009.

The therapeutic vaccine, based on the Company's MVA-BN® technology, is designed to generate cellular and humoral immune responses to PSA and PAP (prostate specific antigen and prostatic acid phosphatase), which are both well-known prostate cancer tumour targets.

About Bavarian Nordic

Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's business strategy is focused in three areas: biodefence, cancer and infectious diseases. Bavarian Nordic's proprietary and patented technology MVA-BN® is one of the world's safest, multivalent vaccine vectors. Bavarian Nordic has ongoing contracts with the US government for the late-stage development and procurement of the company's third-generation smallpox vaccine, IMVAMUNE®. Bavarian Nordic is listed on the OMX Nordic Exchange Copenhagen under the symbol BAVA.
<<



Let’s talk biotech!
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”